normative
Rare Disease Trials Need Early-Evidence Approvals
For diseases with too few patients or very slow progression to test in standard trials, regulators should approve drugs based on mechanistic reasoning, animal data, early human testing, and preliminary biomarker evidence, then collect more rigorous data after market launch.
normativepending
Speaker
AlexEvidence Quote
“we're just never going to get drugs for certain diseases.”
Source
Alex Telford - Unlocking Innovation in Pharma - [Invest Like the Best, EP.360]— Invest Like the BestCreated: 11/14/2026, 6:42:06 AM
Your notes
Loading notes...